Abstract 3596
Background
Cancer immunotherapy, particularly monoclonal antibodies against immune checkpoint inhibitors, has shown surprising efficacy in several types of advanced incurable tumors, including malignant melanoma. Tregs, a subset of lymphocytes involved in immune-surveillance and self-tolerance, are usually increased in melanoma patients. Lymphocytes are particularly rich in FKBP51, the intracellular receptor for FK506 and rapamycin. Melanoma aberrantly expresses this immunophilin, which supports cancer resistance and invasion. Recently, our group has shown that melanoma interaction with immune cells, through PD-L1/PD1, generated the splicing of FKBP5 gene inducing a lower molecular weight form (FKBP51s), in both melanoma and lymphocyte. Aim of this study is to assess the role of Treg FKBP51s+ as potential biomarker of response to anti-PD1 drugs.
Methods
Treg FKBP51s+ were measured in peripheral blood by flow cytometry. To date, we have outcomes of 11 patients. For 6 patients, we have collected from 4 up to 16 blood samples, before each anti-PD1 administration, with a total of 80 sample analysis. iTregs were generated by purified CD4+ T lymphocytes from normal donor, stimulated with CD3+CD28+beads. The suppressive capacity was assessed according to the parameters CD25high, Ki67high and p70S6khigh.
Results
In 5 responder patients, Treg FKBP51s+ was 1.2-4.8%; in 5 non-responders, the count was 0.04-0.8%. Interestingly, a patient with count 0.72% developed autoimmune side effects that led to drug discontinuation. Resolution of side effects was accompanied by an increase in Treg FKBP51s+ value to 9.9%. In vitro iTreg generation suggested that FKBP51s was induced in Treg CD25high Ki67high p70S6khigh, corresponding to a highly metabolically active profile associated with strong suppressive capability. Use of a siRNA for FKBP51s silencing resulted in reduction of this subtype of iTreg.
Conclusions
Our data reinforce the hypothesis that melanoma patients that benefit from immunotherapy are recognizable by an expansion of a Treg subset which plays a central role in tumor immune evasion. This Treg subset is marked by FKBP51s, a splicing protein isoform generated by triggering of surface antigens (PD-L1, PD1) abundantly expressed on highly suppressive Tregs.
Clinical trial identification
Legal entity responsible for the study
Università degli Studi della Campania Luigi Vanvitelli.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5964 - Longitudinal Assessment of Multiplex Patient-Specific ctDNA Biomarkers in Bladder Cancer for Diagnosis, Surveillance, and Recurrence
Presenter: Karin Birkenkamp-Demtröder
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2197 - Distinct functional consequences of HER2 gene amplification in colorectal and lung adenocarcinomas
Presenter: Evgeny Imyanitov
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2422 - Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: independent actors or reciprocal drivers? A translational study by Meet-Uro group
Presenter: Marzia Del Re
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2750 - Validation of a 90-gene assay for tissue origin diagnosis of brain metastases
Presenter: Yulong Zheng
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2960 - Development of a Pan-Cancer Biomarker Panel for Improved Detection of MSI Across all Cancer Types
Presenter: Jeff Bacher
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3791 - bMSI better predicts the responses to immune checkpoint inhibitors (ICI) than MMR/MSI from historical tissue specimens in metastatic gastrointestinal cancer patients
Presenter: Zhenghang Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5189 - Vall d’Hebron Institute of Oncology (VHIO) Immuno-Oncology prognostic index (VIO): a new tool for improved patient (pt) selection in Phase 1 (Ph1) trials with Immune Checkpoint Inhibitors (ICI).
Presenter: Cinta Hierro
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5372 - Augmenting TNM Staging with Machine Learning-based Immune Profiling for Improved Prognosis Prediction in Muscle-Invasive Bladder Cancer Patients
Presenter: Nicolas Brieu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2249 - HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma
Presenter: Alice Bernard-Tessier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2287 - Predicting toxicity and response to pembrolizumab (P) through germline genomic HLA class I analysis
Presenter: Marco Iafolla
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract